Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
Pharmacoepidemiology and Drug Safety · 2025-01 · 34 (1)
DOI: 10.1002/pds.70102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 14.01.2025. Verfasst von William Bai und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Pharmacovigilance, Thiazolidinediones, Adverse Drug Reaction Reporting Systems, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Introduction
Masking is a reporting bias where drug safety signals are muffled by elevated reporting of other medications in spontaneous reporting databases. While the impact of masking is often limited, its effect when using restricted designs, such as active comparators, can be consequential.
Methods
We used data from the US Food and Drugs Administration Adverse Event Reporting System (1999Q3‐2013Q3) to study masking in a real‐world example. Rosiglitazone, a thiazolidinedione with elevated reporting after safety concerns over cardiovascular risks, was the masking candidate. We hypothesized that stimulated reporting masked signals for another thiazolidinedione, pioglitazone. We computed estimates of proportional reporting ratios and information components, using the Bayesian confidence propagation neural network, for pioglitazone‐myocardial infarction and pioglitazone‐cardiac failure under unrestricted and active comparator designs, with and without the mask, before (1999Q3‐2007Q1) and after (2007Q2‐2013Q3) safety concerns. Relative change‐in‐estimates were computed to compare results with and without rosiglitazone.
Results
From 1999Q3‐2007Q1, relative change‐in‐estimates of proportional reporting ratio for pioglitazone‐myocardial infarction was 0.00 in unrestricted design and 0.10 in active comparator, and for pioglitazone‐cardiac failure, the change was 0.01 and 0.62, respectively. From 2007Q2‐2013Q3, relative change‐in‐estimates for pioglitazone‐myocardial infarction was 0.41 in unrestricted design and 18.00 in active comparator; the change for pioglitazone‐cardiac failure was 0.04 and 1.03, respectively. Relative changes in estimates of information component mirrored these trends.
Conclusions
Masking can influence signal detection in active comparator designs where external events impact reporting rates in reference sets. Evaluating masking in related contexts is essential for drug safety monitoring and resource allocation for follow‐up studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
- Institute of Clinical Pharmacology and Toxicology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Department of Mathematics and Statistics, University of Ottawa, Ottawa, Ontario, Canada.
ORCID-Profile: Antonios Douros
Zitieren
APA
Bai, W., Douros, A., & Gravel, C. A. (2025). Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events. Pharmacoepidemiology and Drug Safety, 34(1). https://doi.org/10.1002/pds.70102
Vancouver
Bai W, Douros A, Gravel CA. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events. Pharmacoepidemiology and Drug Safety. 2025;34(1). doi:10.1002/pds.70102
BibTeX
@article{Bai2025,
author = {Bai, William and Douros, Antonios and Gravel, Christopher A},
title = {Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
volume = {34},
number = {1},
doi = {10.1002/pds.70102}
}
EUVIMED